

Digital Microfluidic System Integrated with Electrochemical Sensor for Multiplexed Monitoring of Immune Responses to Immunotherapy

Presenting Author: Yuqian Zhang

Primary Investigator: Yuguang Liu

Department of Physiology and Biomedical Engineering
Microbiome Program, Center for Individualized Medicine

Department of Immunology, Mayo Clinic

Department of Surgery, Division of Surgical Research

Mayo Clinic, Rochester, MN 55905, USA

Immunotherapy:

Immune checkpoint inhibitor

- Down-regulation of T cell response to tumor cells
- Can be blocked by antibodies


Challenges of Immunotherapy

- *Low response rate: 15 to 20%*
- *High cost: \$200,000 per patient per year*
- *Heterogeneity* in therapeutic responses

Potential solutions:

- Continuously monitor the therapeutic responses
- Detecting multiple biomarkers for a more comprehensive assessment:
 - Peripheral blood mononuclear cell (PBMC)
 - Soluble PD-L1 protein (sPD-L1)
 - Extracellular vesicles PD-L1 (evPD-L1)

Anti-PD 1/PD-L1 therapies



<https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors>


© 2015 Terese Winslow LLC. All rights reserved. has certain rights

Peripheral blood mononuclear cell (PBMC)

- Key drivers of the immune responses to pathogens
- Provide a window into patient's immune response to immune checkpoint inhibitor
- Comprised of multiple immune cell subsets, providing a more comprehensive overview of the immune status

❑ Standard detection method: Flow cytometry



- ✗ Highly specialized and bulky equipment in core facilities
- ✗ Unrealistic to regularly monitor changes in immune functions




Digital Microfluidic (DMF) System integrated with electrochemical sensor

□ Digital microfluidic lab-on-chip:




- Manipulation of discrete droplets
- Electrowetting-on-dielectric (EWOD)
- Automated and programmable, reconfigured on-demand



- Integrated DMF system
- DropBot operation system
- Droplet control panel




Layout of the integrated DMF device





Overview of DMF device with integrated interdigitated electrodes:

- **bottom plate:** actuation electrode array to manipulate droplet
- **top plate:** IDE sensing electrode embedded in Indium Tin Oxide (ITO) ground electrode

Quantification of PBMC abundance: thiol-carboxyl self-assembled monolayer (SAM) + Cell assay



Dynamic incubation mode: forward-backward-backward-forward




- Low sample volume (4 μ L) for rapid detection (20 min)
- 2.4X enhanced detection signal in dynamic mode
- Detect as low as 10^4 PBMCs/mL, ~two orders of magnitude less than the biologically relevant range (0.7–6.2* 10^6 cells per mL of blood)

Soluble PD-L1 protein (sPD-L1)

- The first functionally characterized ligand of the coinhibitory programmed death receptor 1 (PD-1)
- PD-L1 expression is generally associated with *poor prognosis*

❑ Conventional detection method: ELISA





- ✗ Labor-intensive
- ✗ Extended turnaround time: sensitivity \propto hybridization time
 - Best sensitivity performance (8 pg/ml) for commercial sPD-L1 ELISA kit



□ **A 3-dimensional microstructure for PD-L1 capture**



- Reduced graphene oxide (rGO): large surface area, high conductivity
- Bovine serum albumin (BSA): reduce the non-specific binding
- Glutaraldehyde (GA): cross-link BSA molecules to create a 3D protein matrix

□ **SEM characterization**







❑ Electrochemical validation of immunoassay

- The formation of sandwich immunoassay
- Signal shifting: the inhibition of charge transfer between the sensor surface and the electrolyte solution




Quantitative detection of sPD-L1 with electrochemical biosensor

- Able to detect sPD-L1 concentration down to 1 pg/mL
- High specificity



Electrochemical biosensor integrated with digital microfluidic platform





Extracellular vesicles PD-L1 (evPD-L1)

- EV derived PD-L1 has a similar function to tumor PD-L1.
- EvPD-L1 binds to PD-1 on T cells, induce T cell apoptosis, and inhibit T cell activation and proliferation







❑ Conventional separate and detection methods

- Ultracentrifugation
 - ✗ Large sample volume, bulky instrumentation
 - ✗ Time-consuming
- Western blot/nano-flow cytometry
 - ✗ Labor-intensive
 - ✗ Require sample pre-concentration



❑ On-chip separation and detection of evPD-L1

- Immunomagnetic separation on DMF chip: 2 hours, automated; ~ 6X higher capture efficiency
- Qualitative detection of EVPD-L1 with electrochemical sensor



□ Summary

- A novel DMF platform integrated with multiplexed electrochemical sensors to detect PBMCs, sPD-L1 and evPD-L1.
- Dynamic incubation enhances hybridization.
- Integrate sample prep and detection, 2 hours turnaround time.

□ Examples of utility

- Pretreatment evaluation: PD-L1+ EVs >0.55 ng/ml: T cell over-exhaustion
- In-treatment evaluation: >2.08X changes in PD-L1+ EVs reflect successful anti-tumor immunity

□ Acknowledgements



Yuguang Liu, Ph.D.
Associate Consultant
Department of Physiology
& Biomedical Engineering
Mayo Clinic, USA



Alexander Revzin, Ph.D.
Consultant
Department of Physiology
& Biomedical Engineering
Mayo Clinic, USA



**Haidong Dong, M.D.,
Ph.D.**, Consultant,
Department of Urology
Department of
Immunology



**Fabrice Lucien-
Matteoni, Ph.D.**
Assistant professor
Department of
Immunology



Funding resources: NIH; Ivan Bowen
Family Foundation, Mayo Clinic.



- Department of Surgery
- Department of Physiology & Biomedical Engineering
- Microbiome Program, Center for Individualized Medicine



National Institutes
of Health

Thank you for listening! Any questions?

